Browse Studies — Arctuva

Phase 2

A Phase 2a, Multi-Center, Placebo-Controlled, Double-Blinded, Randomized, Dose Ranging Study of the Preliminary Efficacy of DARE-HPV to Treat Persistent High-Risk Human Papillomavirus (HPV) Genital Infection

The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital…

Human Papilloma Virus (HPV)High-risk Human Papillomavirus Infection

Estimated

~$10 – $8,750

Daré Bioscience, Inc.NCT07601074

Observational

NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial LMI-001-A-S04

This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cer…

Cervical CarcinomaHuman Papillomavirus Infection

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07281430

Observational

Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents

The purpose of this study is to determine the provider- and practice-level characteristics that influence the impact of implementation strategies guided by pra…

Human Papillomavirus Infection

Estimated

~$10 – $6,250

The University of Texas Health Science Center, HoustonNCT06598475

Observational

Appalachian Voices for Health - Feasibility Trial of a Multi-level Media Production and Social Marketing Campaign to Reduce HPV Vaccine Hesitancy

Since 2019, the HPV working group of the University of Virginia Cancer Center's Southwest Virginia Community Advisory Board has developed and executed strategi…

Human Papillomavirus InfectionVaccination Hesitancy

Estimated

~$10 – $6,250

University of VirginiaNCT05860725